DRIO Quote, Financials, Valuation and Earnings

Mitesco, Inc. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of -106766.67%. DarioHealth Corp.'s return on equity of -41.55% beat Mitesco, Inc.'s return on equity of --.

DarioHealth Corp. has a consensus price target of $18.00, signalling upside risk potential of 59.65%. On the other hand Mitesco, Inc. has an analysts' consensus of -- which suggests that it could grow by 305.16%. Given that Mitesco, Inc. has higher upside potential than DarioHealth Corp., analysts believe Mitesco, Inc. is more attractive than DarioHealth Corp..

DarioHealth Corp. has a beta of 1.161, which suggesting that the stock is 16.051% more volatile than S&P 500. In comparison Mitesco, Inc. has a beta of 5.563, suggesting its more volatile than the S&P 500 by 456.284%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mitesco, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DarioHealth Corp. pays -- of its earnings as a dividend. Mitesco, Inc. pays out -- of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are larger than Mitesco, Inc. quarterly revenues of $3K. DarioHealth Corp.'s net income of -$2.1M is higher than Mitesco, Inc.'s net income of -$3.2M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while Mitesco, Inc.'s PE ratio is 2.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 6.26x versus 24.83x for Mitesco, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National Research Corp. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of 5.11%. DarioHealth Corp.'s return on equity of -41.55% beat National Research Corp.'s return on equity of 51.49%.

DarioHealth Corp. has a consensus price target of $18.00, signalling upside risk potential of 59.65%. On the other hand National Research Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that DarioHealth Corp. has higher upside potential than National Research Corp., analysts believe DarioHealth Corp. is more attractive than National Research Corp..

DarioHealth Corp. has a beta of 1.161, which suggesting that the stock is 16.051% more volatile than S&P 500. In comparison National Research Corp. has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.981%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National Research Corp. offers a yield of 3.8% to investors and pays a quarterly dividend of $0.16 per share. DarioHealth Corp. pays -- of its earnings as a dividend. National Research Corp. pays out 100.39% of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than National Research Corp. quarterly revenues of $35.2M. DarioHealth Corp.'s net income of -$2.1M is lower than National Research Corp.'s net income of $1.8M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while National Research Corp.'s PE ratio is 26.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 6.26x versus 2.23x for National Research Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Spok Holdings, Inc. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of 9.46%. DarioHealth Corp.'s return on equity of -41.55% beat Spok Holdings, Inc.'s return on equity of 10.88%.

DarioHealth Corp. has a consensus price target of $18.00, signalling upside risk potential of 59.65%. On the other hand Spok Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 54.87%. Given that DarioHealth Corp. has higher upside potential than Spok Holdings, Inc., analysts believe DarioHealth Corp. is more attractive than Spok Holdings, Inc..

DarioHealth Corp. has a beta of 1.161, which suggesting that the stock is 16.051% more volatile than S&P 500. In comparison Spok Holdings, Inc. has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.512%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spok Holdings, Inc. offers a yield of 9.22% to investors and pays a quarterly dividend of $0.31 per share. DarioHealth Corp. pays -- of its earnings as a dividend. Spok Holdings, Inc. pays out 171.77% of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than Spok Holdings, Inc. quarterly revenues of $33.9M. DarioHealth Corp.'s net income of -$2.1M is lower than Spok Holdings, Inc.'s net income of $3.2M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while Spok Holdings, Inc.'s PE ratio is 16.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 6.26x versus 2.01x for Spok Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vaso Corp. has a net margin of -41.48% compared to DarioHealth Corp.'s net margin of 7.55%. DarioHealth Corp.'s return on equity of -41.55% beat Vaso Corp.'s return on equity of 9.61%.

DarioHealth Corp. has a consensus price target of $18.00, signalling upside risk potential of 59.65%. On the other hand Vaso Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that DarioHealth Corp. has higher upside potential than Vaso Corp., analysts believe DarioHealth Corp. is more attractive than Vaso Corp..

DarioHealth Corp. has a beta of 1.161, which suggesting that the stock is 16.051% more volatile than S&P 500. In comparison Vaso Corp. has a beta of 0.466, suggesting its less volatile than the S&P 500 by 53.413%.

DarioHealth Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vaso Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DarioHealth Corp. pays -- of its earnings as a dividend. Vaso Corp. pays out -- of its earnings as a dividend.

DarioHealth Corp. quarterly revenues are $5M, which are smaller than Vaso Corp. quarterly revenues of $22.7M. DarioHealth Corp.'s net income of -$2.1M is lower than Vaso Corp.'s net income of $1.7M. Notably, DarioHealth Corp.'s price-to-earnings ratio is -- while Vaso Corp.'s PE ratio is 11.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DarioHealth Corp. is 6.26x versus 0.35x for Vaso Corp.. Usually stocks with elevated PS ratios are considered overvalued.